Wallace M/LinkedIn
Jan 3, 2026, 14:08
Wallace M Shares a SWOT Analysis of Aqvesme’s FDA Approval
Wallace M, CEO and Founder of i3consult.com, shared on LinkedIn:
”FDA APPROVAL UPDATE: Aqvesme™ (mitapivat) for Thalassemia‑Related Anemia
The FDA approval of Aqvesme™ introduces the first oral, disease‑modifying therapy for anemia in adults with alpha‑ or beta‑thalassemia.
Our latest SWOT analysis explores the clinical significance and strategic implications of this milestone.
Read the full analysis.”
Stay updated with Hemostasis Today.
-
Apr 5, 2026, 10:33Vidya Kollu: Simplifying Hematology Without Losing Clinical Depth
-
Apr 5, 2026, 09:56Augustina Isioma Ikusemoro: Blood as a Living System of Survival, Protection, Identity, and Healing
-
Apr 5, 2026, 08:19Alan Nurden: Disrupting Pathogenic Alleles in VWD Through Gene Editing
-
Apr 5, 2026, 05:32Preeti Sinha: Molecular Mechanisms of Atherosclerosis
-
Apr 5, 2026, 05:28Alessandra Bosch: Exploring Haemostasis in Children
-
Apr 5, 2026, 05:19Chris Centeno: What If You Could Delay Aging and Improve Cognition with Regular Blood Therapy?
-
Apr 4, 2026, 18:08Anirban Sen Gupta: Dante Disharoon’s Research on PlateChek Featured on JTH April 2026 Cover
-
Apr 4, 2026, 18:06Domenico Girelli: WHO 2024 Guidelines Reveal Higher Global Anemia Burden and Epidemiological Shift
-
Apr 4, 2026, 18:04Fotios Barkas: Exploring The Bidirectional Relationship Between Frailty and Stroke